-
Mashup Score: 10
Is Apolipoprotein E a new biomarker for DDD and C3GN? NSMC Intern Dr Jasmine Sethi decodes the recent study visually
Source: www.nephjc.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 88
This week, we will discuss the role of ApoE in determining the subtypes of C3 Glomerulopathy.
Source: www.nephjc.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 28
Is Apolipoprotein E a new biomarker for DDD and C3GN? NSMC Intern Dr Jasmine Sethi decodes the recent study visually
Source: www.nephjc.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 88
This week, we will discuss the role of ApoE in determining the subtypes of C3 Glomerulopathy.
Source: www.nephjc.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 24
FSGS is hard and the data sucks. But here comes sparsentan fresh off its win in the PROTECT trial for IgA Nephropathy. Can it pull another rabbit out of the hat for patients that suffer from FSGS or are we doomed to forever treating our patients with Acthar® Gel?
Source: www.nephjc.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 24
FSGS is hard and the data sucks. But here comes sparsentan fresh off its win in the PROTECT trial for IgA Nephropathy. Can it pull another rabbit out of the hat for patients that suffer from FSGS or are we doomed to forever treating our patients with Acthar® Gel?
Source: www.nephjc.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 24
FSGS is hard and the data sucks. But here comes sparsentan fresh off its win in the PROTECT trial for IgA Nephropathy. Can it pull another rabbit out of the hat for patients that suffer from FSGS or are we doomed to forever treating our patients with Acthar® Gel?
Source: www.nephjc.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1Sparsentan in IgA Nephropathy : The PROTECT trial — NephJC - 13 day(s) ago
This week, we will discuss another IgA Nephropathy trial – Sparsentan this time. A dual endothelin antagonist and angiotensin receptor antagonist.
Source: www.nephjc.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 3Keep Calm and Carry on Inhibiting the RAS — NephJC - 13 day(s) ago
This week, we will discuss the STOP ACEi trial, a poster from Kidney Week but published in the NEJM. Should we stop RAS inhibition at an arbitrary GFR or bravely carry on?
Source: www.nephjc.comCategories: General Medicine News, NephrologyTweet-
On STOPACEi_trial (see https://t.co/HulgLZGGz2) We should not interpret that as ‘RASi do not reduce kidney failure’ But as ‘RASi decrease CV events’ and do not increase kidney failure risk? She showed this TTE - but not @FuEdouard TTE which IMO was more rigorous? #ISNWCN https://t.co/xg6Qsd6M02
-
-
Mashup Score: 30
This week, we will discuss some groundbreaking work on elucidating the adaptive and maladaptive cellular transcription and gene activation of the kidney in healthy and diseased states.
Source: www.nephjc.comCategories: General Medicine News, NephrologyTweet
Check out this 🤩 AMAZING 🤩 visual abstract by @JasmineNephro https://t.co/q2E1AWrW0U #nephjc https://t.co/CRAV3vECV5